Abstract
There was a greater than 50% decline in central nervous system (CNS) drug discovery and development programs by major pharmaceutical companies from 2009 to 2014. This decline was paralleled by a rise in the number of university led drug discovery centers, many in the CNS area, and a growth in the number of public-private drug discovery partnerships. Diverse operating models have emerged as the academic drug discovery centers adapt to this changing ecosystem.
Original language | English (US) |
---|---|
Pages (from-to) | 429-431 |
Number of pages | 3 |
Journal | ACS Chemical Neuroscience |
Volume | 8 |
Issue number | 3 |
DOIs | |
State | Published - Mar 15 2017 |
Keywords
- Academic drug discovery
- public-private partnerships
ASJC Scopus subject areas
- Biochemistry
- Physiology
- Cognitive Neuroscience
- Cell Biology